Eli Lilly’s SWOT analysis: stock poised for growth amid obesity market boom

Eli Lilly and Company (NYSE:LLY), a global pharmaceutical giant valued at $759.48 billion, has been making waves in the healthcare sector with its strong focus on diabetes, obesity, and oncology treatments. As the company continues to solidify its position as a leader in the rapidly expanding glucagon-like peptide-1 (GLP-1) and obesity markets, investors and analysts are closely watching its performance and future prospects. According to InvestingPro, LLY maintains a "GREAT" financial health score of 3.14, reflecting its strong market position. This comprehensive analysis delves into Eli Lilly’s current standing, recent developments, and potential challenges as it navigates an increasingly competitive landscape.

Recent Performance and Financial Highlights

Eli Lilly has demonstrated robust financial performance in recent quarters, with significant year-over-year growth in both top and bottom lines. The company’s revenue grew 36.83% in the last twelve months, with earnings per share reaching $15.29, showcasing the strength of its core business segments. With a gross profit margin of 82.64%, LLY demonstrates strong operational efficiency in its pharmaceutical operations.

Key products driving this growth include Mounjaro (tirzepatide) and Zepbound, which have shown strong sales momentum and market penetration. Mounjaro, in particular, has been gaining market share in the diabetes treatment space and is expanding internationally. Zepbound, Eli Lilly’s obesity treatment, has also exceeded expectations, contributing to the company’s overall positive performance.

Analysts project continued growth for Eli Lilly, with BMO Capital Markets estimating EPS to reach $21.86 for 2025 and revenue to hit $58,933 million in the same year. These projections reflect the market’s confidence in Eli Lilly’s ability to capitalize on the growing demand for its innovative treatments. InvestingPro data shows analyst targets ranging from $650 to $1,190, with consensus recommendations leaning strongly toward "Buy."

Want deeper insights? Access comprehensive analysis and 15+ additional ProTips about LLY through InvestingPro, including exclusive Fair Value estimates and financial health metrics.

Product Portfolio and Pipeline

Eli Lilly’s product portfolio is anchored by its strong presence in the GLP-1 and obesity treatment markets. Mounjaro and Zepbound are at the forefront of this portfolio, with both drugs showing promising results in clinical trials and real-world applications.

The company’s pipeline is equally impressive, with several potential blockbuster drugs in development. One of the most anticipated candidates is orforglipron, an oral GLP-1 receptor agonist that has shown promising results in Phase 3 trials for both diabetes and obesity treatment. Analysts expect orforglipron to potentially launch for obesity treatment by 2026, further strengthening Eli Lilly’s position in this rapidly growing market.

In addition to its GLP-1 and obesity treatments, Eli Lilly is also making strides in other therapeutic areas. The company’s oncology franchise is expected to contribute significantly to future growth, and recent approvals like donanemab for Alzheimer’s disease showcase the diversity of Eli Lilly’s research and development efforts.

Market Position and Competition

Eli Lilly has established itself as a leader in the GLP-1 and obesity treatment markets, competing directly with companies like Novo Nordisk. The company’s market share in these segments has been growing, with Mounjaro now leading over Novo Nordisk’s offerings in some markets.

However, the competitive landscape remains intense. Recent developments, such as the agreement between Novo Nordisk and CVS Caremark, have raised concerns about potential pricing pressures and market share dynamics. Despite these challenges, analysts believe that Eli Lilly’s strong product portfolio and pipeline position it well to maintain its competitive edge. The company’s stability is evidenced by its 55-year track record of maintaining dividend payments, with a current dividend yield of 0.71% and 15.38% dividend growth in the last twelve months.

Regulatory and Legal Developments

Eli Lilly has recently experienced a significant legal victory that could have positive implications for its business. In September 2025, a federal judge ruled in favor of Eli Lilly in a case against Henry Meds, a telehealth company accused of unlawfully marketing and selling compounded versions of tirzepatide. This ruling is seen as a positive development for Eli Lilly, as it may help protect branded volume, pricing power, and reduce off-label substitution risk.

The company is also navigating the evolving regulatory landscape, particularly in relation to drug pricing negotiations and potential policy changes. The removal of the "pill penalty" for small molecule drugs could benefit Eli Lilly’s products like Verzenio and orforglipron, potentially delaying price negotiations and enhancing sales prospects.

Future Outlook and Growth Drivers

Eli Lilly’s future outlook remains positive, with several key growth drivers on the horizon. The company’s continued focus on diabetes and obesity treatments is expected to drive durable growth, supported by a strong pipeline of innovative therapies.

Upcoming catalysts include the potential approval and launch of orforglipron, as well as data readouts from various clinical trials. The ATTAIN-1 and ATTAIN-2 obesity studies for orforglipron are particularly anticipated, with results expected to inform regulatory submissions for obesity treatment by late 2025.

Additionally, Eli Lilly’s expansion into new therapeutic areas, such as pain management through the acquisition of SiteOne Therapeutics, demonstrates the company’s commitment to diversifying its portfolio and exploring new avenues for growth.

Bear Case

How might increased competition impact Eli Lilly’s market share?

The GLP-1 and obesity treatment markets are becoming increasingly competitive, with several pharmaceutical companies vying for market share. Novo Nordisk, in particular, has been a strong competitor, and its recent agreement with CVS Caremark has raised concerns about potential pricing pressures and market access challenges for Eli Lilly.

As more players enter the market and existing competitors strengthen their positions, Eli Lilly may face challenges in maintaining its current market share. The company will need to continue innovating and differentiating its products to stay ahead of the competition. Additionally, potential pricing wars could impact profitability, even if market share is maintained.

What risks does Eli Lilly face in terms of regulatory challenges?

Eli Lilly operates in a highly regulated industry, and changes in healthcare policies or drug pricing regulations could significantly impact its business. The ongoing discussions around drug pricing reform in the United States pose a potential risk to Eli Lilly’s revenue and profitability.

Furthermore, as the company expands globally, it must navigate complex regulatory environments in different countries. Any delays in regulatory approvals or unexpected changes in regulatory requirements could hinder Eli Lilly’s growth plans and impact its financial performance.

Bull Case

How could Eli Lilly’s pipeline contribute to future growth?

Eli Lilly’s robust pipeline, particularly in the GLP-1 and obesity treatment space, positions the company for strong future growth. The potential approval and launch of orforglipron could be a significant catalyst, as it would provide an oral option in a market currently dominated by injectable treatments.

Moreover, the company’s ongoing research in areas such as Alzheimer’s disease, oncology, and pain management could lead to breakthrough therapies that open up new revenue streams. The diversity of Eli Lilly’s pipeline helps mitigate risk and provides multiple avenues for growth in the coming years.

What advantages does Eli Lilly have over its competitors in the GLP-1 space?

Eli Lilly has established a strong presence in the GLP-1 market with products like Mounjaro and Zepbound. The company’s early success in this space has allowed it to build brand recognition and gain valuable real-world data on the efficacy and safety of its treatments.

Additionally, Eli Lilly’s focus on developing oral GLP-1 treatments, such as orforglipron, could give it a competitive edge in a market that is currently dominated by injectable therapies. The potential for improved patient compliance and convenience with oral treatments could help Eli Lilly capture a larger share of the market and potentially expand the overall patient population for GLP-1 therapies.

SWOT Analysis

Strengths

• Strong product portfolio in diabetes and obesity treatments
• Market leadership in GLP-1 therapies
• Robust pipeline with potential blockbuster drugs
• Diversified research and development efforts across multiple therapeutic areas
• Strong financial performance and growth trajectory

Weaknesses

• Manufacturing capacity constraints for key products
• Dependence on a few key products for significant portion of revenue
• Exposure to potential pricing pressures in competitive markets

Opportunities

• Expanding obesity treatment market with growing global demand
• Potential for oral GLP-1 treatments to capture larger market share
• Expansion into new therapeutic areas through acquisitions and partnerships
• Increasing prevalence of diabetes and obesity worldwide

Threats

• Intense competition in the GLP-1 and obesity treatment markets
• Regulatory challenges and potential drug pricing reforms
• Patent expirations and generic competition for established products
• Global economic uncertainties impacting healthcare spending

Analysts Targets

• Cantor Fitzgerald: $825.00 (September 29th, 2025)
• BMO Capital Markets: $840.00 (September 17th, 2025)
• Cantor Fitzgerald: $975.00 (June 23rd, 2025)
• BMO Capital Markets: $900.00 (May 28th, 2025)
• BMO Capital Markets: $900.00 (May 2nd, 2025)
• Cantor Fitzgerald: $975.00 (May 2nd, 2025)
• HSBC Global Research: $700.00 (April 28th, 2025)
• Berenberg: $970.00 (March 24th, 2025)

In conclusion, Eli Lilly and Company stands at a pivotal moment in its history, with strong market positioning in the rapidly growing GLP-1 and obesity treatment markets. InvestingPro analysis indicates the stock is currently trading slightly above its Fair Value, with an RSI suggesting overbought territory.

Make smarter investment decisions with InvestingPro’s comprehensive research report, which provides detailed analysis of LLY’s valuation, growth prospects, and risk factors. Join over 130,000 investors who trust our professional-grade tools and insights. The company’s robust pipeline, particularly the potential of orforglipron, coupled with its established products like Mounjaro and Zepbound, provide a solid foundation for future growth. However, Eli Lilly must navigate challenges such as intense competition, regulatory uncertainties, and potential pricing pressures to maintain its leadership position. As the healthcare landscape continues to evolve, Eli Lilly’s ability to innovate and adapt will be crucial in determining its long-term success in the pharmaceutical industry.

This analysis is based on information available up to October 8, 2025, and does not include any subsequent developments or market changes.

InvestingPro: Smarter Decisions, Better Returns

Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on LLY. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore LLY’s full potential at InvestingPro.

Should you invest in LLY right now? Consider this first:

Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if LLY is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.

To evaluate LLY further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if LLY appears on our undervalued or overvalued stock lists.

These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.